Yenepoya University Transfers Patent for Self-Disinfecting Toothbrush to Dental-Tech Startup

by

Yenepoya (Deemed to be University) has transferred its newly granted patent for a self-disinfecting toothbrush to Fuwu Solutions LLP, a dental-tech startup incubated at the Yenepoya Technology Incubator (YTI). The agreement was formalized on September 11, 2025, marking a milestone for both academic research and healthcare innovation in India.

Patent Details

The innovation is titled “Toothbrush with built-in self-disinfectant” and carries application number 202441080875. The patented design allows the toothbrush to disinfect itself after every use. This feature is aimed at preventing microbial contamination and reducing the risk of oral reinfections — a challenge often overlooked in routine dental care.

According to Yenepoya University, the invention is currently in the pre-commercialization stage. The transfer will enable Fuwu Solutions LLP to take the technology forward for prototyping, testing, and eventual mass production.

Startup Linkage

Fuwu Solutions LLP is a dental-tech startup nurtured under the Yenepoya Technology Incubator, which has been supporting innovations in medical and healthcare technologies. By securing this patent, the startup strengthens its intellectual property base and gains an edge in developing products tailored for both domestic and global dental markets.

The incubator’s role highlights how universities can act as a bridge between research innovation and market application.

Health and Policy Significance

The toothbrush addresses an often-ignored issue — hygiene of oral care devices. Most users simply rinse toothbrushes after use, leaving them prone to microbial build-up. A self-disinfecting feature ensures a higher level of oral safety, particularly important in regions with limited access to hygienic storage conditions.

This innovation directly supports the United Nations Sustainable Development Goal (SDG-3: Good Health & Well-Being). It also resonates with India’s “Make in India” initiative by promoting home-grown research and manufacturing.

Expert Remarks

Representatives from Yenepoya University emphasized that the technology transfer showcases the institution’s commitment to translational research. They highlighted that collaborations with startups accelerate the journey of ideas from labs to society.

Fuwu Solutions LLP expressed confidence in commercializing the toothbrush in the near future. The startup plans to refine the design, test cost-effective production models, and explore regulatory pathways for clinical approval.

Looking Ahead

With rising awareness of oral health and hygiene, the self-disinfecting toothbrush has strong market potential. If successfully commercialized, it could reduce oral infections, improve dental care routines, and set a benchmark for next-generation oral hygiene products.

The patent transfer underscores a growing trend in India’s research ecosystem — where universities don’t just create intellectual property but also ensure its real-world impact through startup collaborations.

Affle 3i Secures US Patent for Advanced Fraud Detection Engine

by

Affle 3i has strengthened its intellectual property portfolio with a new United States patent for its fraud detection engine. This marks the company’s 16th US patent and underlines its focus on innovation in digital advertising.

The patent, titled “Method and System for Hardware and Software Based User Identification for Advertisement Fraud Detection,” covers a multi-layered approach to identifying fraudulent activity.

Multi-Layered Fraud Detection

The system uses both hardware and software signals to verify user authenticity. It tracks device sensors, biometric inputs, connectivity data, and user behavior in real time. The technology creates unique digital fingerprints that help distinguish genuine users from bots or manipulated activity.

Affle 3i has also integrated machine learning algorithms to keep the system adaptive. The engine applies supervised and unsupervised learning methods to respond to new fraud tactics. This ensures advertisers can block suspicious devices and publishers with greater accuracy.

Broader Device Coverage

The patented solution extends beyond smartphones. It also works with wearables, IoT devices, and connected TVs. Signals such as touch interactions, gyroscope readings, and accelerometer data further improve fraud detection.

According to industry reports, ad fraud costs companies billions each year. By reducing invalid traffic and fraudulent impressions, Affle 3i aims to improve campaign efficiency and boost advertiser confidence.

Strengthening Affle’s Position

This development reinforces Affle’s position in the ad tech industry. The company has steadily expanded its intellectual property base, securing multiple patents in recent years. With the latest addition, Affle 3i demonstrates its commitment to fighting ad fraud and delivering value to brands.

The innovation also aligns with the company’s focus on cross-device identification and real-time optimization. By combining advanced data signals with artificial intelligence, Affle 3i continues to push the boundaries of ad verification.

Future Outlook

While the patented technology enhances fraud detection, Affle will also need to ensure compliance with privacy regulations such as GDPR and CCPA. The use of biometric and sensor data requires strong safeguards to protect user privacy.

Nevertheless, the patent is a major step in building a robust, scalable, and future-ready fraud detection framework. Advertisers, agencies, and platforms are expected to benefit from reduced leakage and improved return on ad spend.

For more updates on patent news, check our coverage on Apple’s AR/XR patent and Samsung’s wearable display patent.

Apple Patent Unlocks High-Throughput, Low-Power Signaling for AR/XR Wearables

by

Apple has secured a new patent that could reshape the future of augmented reality (AR) and extended reality (XR) devices. The filing describes a signaling system that delivers high data throughput while consuming minimal power. This breakthrough addresses two of the biggest hurdles for wearable technology — battery efficiency and real-time performance.

The Patent at a Glance

The patent outlines methods and devices that manage data transmission between sensors, displays, and processors in a wearable. Apple’s system combines analog and digital signaling to ensure fast data flow without draining battery power. It leverages amplitude shift keying (ASK) and quadrature amplitude modulation (QAM) for uplink signals, which balance speed with energy savings.

According to the claims, the system also uses control circuitry and power amplifiers to optimize how signals are processed. This design helps reduce signal loss, minimize heat generation, and extend the operating time of wearable devices.

Why It Matters for AR/XR

Apple has made significant investments in spatial computing. Devices like the Apple Vision Pro have shown the company’s push into mixed reality experiences. However, bulky form factors and limited battery life remain barriers to widespread adoption.

The newly patented signaling technology could help Apple:

  • Build lighter and slimmer headsets.
  • Enable higher-resolution displays with smoother frame rates.
  • Support multiple sensors like LiDAR and advanced cameras.
  • Deliver longer battery life for extended AR/XR sessions.

Industry Impact

Efficient signaling is vital for next-generation wearables. Competing companies such as Meta and Samsung are also racing to solve the same challenge. By protecting this innovation, Apple strengthens its intellectual property portfolio and gains an edge in the wearable market.

Experts believe this could mark a turning point for consumer-grade AR glasses, moving them from niche gadgets to mainstream devices.

Looking Ahead

Apple’s patent shows its determination to lead in next-gen wearable computing. If implemented in future products, users could experience seamless AR/XR visuals, longer sessions, and more natural interactions without being tethered to heavy hardware.

This innovation may not appear immediately, but it lays the foundation for Apple’s next wave of AR/XR wearables, potentially transforming how people work, play, and communicate.

Silo Pharma Secures Japanese Patent for PTSD Treatment Technology

by

Silo Pharma Inc. (NASDAQ: SILO) has received a new boost in its global intellectual property strategy. The company announced that the Japan Patent Office granted Patent No. 7683882 for its PTSD treatment technology. The invention, titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress,” was developed at Columbia University and is licensed exclusively to Silo Pharma.

Expanding Global Patent Portfolio

The patent protects SPC-15, Silo’s intranasal drug candidate designed to target post-traumatic stress disorder (PTSD) and other stress-related psychiatric conditions. SPC-15 is a serotonin 5-HT4 receptor agonist that aims to reduce anxiety and improve stress resilience.

This new protection in Japan follows the company’s recent Australian patent approval for the same technology. Together, these patents strengthen Silo Pharma’s international IP portfolio, covering two major global markets.

CEO Highlights Strategic Advantage

Eric Weisblum, Chief Executive Officer of Silo Pharma, emphasized the importance of the development.
“This Japanese patent adds another layer of protection for SPC-15,” he said. “It expands our global patent estate and positions us well for future licensing or commercial opportunities.”

Weisblum also highlighted the company’s partnership with Columbia University, noting that the exclusive global rights to SPC-15 provide a competitive edge in the biotech market.

Regulatory Pathway and Clinical Progress

Silo Pharma plans to pursue the FDA’s 505(b)(2) regulatory pathway for SPC-15. This route may allow the company to rely on existing safety data, potentially accelerating approval timelines and reducing costs.

The company has already completed an FDA-requested 7-day large animal safety study, which showed no toxicities and systemic exposure comparable to oral treatments. Additional preclinical and device studies are underway. These studies also involve Silo’s microchip-enabled nasal delivery system, designed to optimize intranasal dosing. Results from these evaluations are expected later this year.

Broader Development Pipeline

While SPC-15 remains a key asset, Silo Pharma is also advancing a broader neurology-focused pipeline. Current projects include:

  • SP-26: Targeting fibromyalgia and chronic pain.
  • SPC-14: Investigated for Alzheimer’s disease.
  • SPU-16: Focused on multiple sclerosis.

Each program is in preclinical or early development stages. Together, they reflect the company’s goal to address unmet needs in psychiatric and neurological disorders.

Market Context

Silo Pharma is a development-stage biopharmaceutical company with a small market capitalization. Despite its size, the company has been steadily building value through strategic patents and academic collaborations. Its dual focus on drug development and digital asset treasury management adds another layer of differentiation in the biotech sector.

Why It Matters

PTSD affects millions worldwide, with limited treatment options available. The approval of SPC-15’s patent in Japan adds critical international protection to a drug that could potentially reshape PTSD care. For Silo Pharma, this milestone not only enhances its pipeline but also strengthens its licensing and commercialization prospects in Asia and beyond.

Microsoft Files Patent to Combat AI Bias in Search and Ranking Systems

by

Microsoft has taken a major step to address one of artificial intelligence’s biggest challenges—bias. The tech giant recently filed a patent that outlines a system designed to deliver fairer and more relevant results across its platforms.

The patent focuses on building a ranking engine that reduces skewed outputs. It targets AI-driven services such as Bing and Microsoft Copilot, where users rely heavily on search rankings and recommendations. By rethinking how algorithms prioritize results, Microsoft aims to limit bias and strengthen trust in its AI tools.

Why Bias Matters in AI

AI bias has long been a concern for researchers, regulators, and users. Search engines and recommendation systems often mirror existing inequalities in data. This can lead to unfair outcomes, distorted information, or reinforcement of stereotypes.

For Microsoft, solving this problem is not only about user trust. It is also a competitive advantage in a market where AI ethics is becoming a core differentiator. Rival companies like Google, OpenAI, and Anthropic are also working on fairness and transparency. Microsoft’s patent shows it wants to stay ahead in this race.

Inside the Patent

The system described in Microsoft’s filing goes beyond standard ranking models. It introduces methods to evaluate and adjust results based on fairness criteria. The patent suggests algorithms can balance accuracy with equitable distribution of information.

While the filing does not reveal every detail, it points to a flexible framework. The technology can adapt to different contexts—whether a user is searching the web, asking Copilot a question, or using enterprise AI tools.

The patent also emphasizes user relevance. It seeks to ensure that results are not only unbiased but also meaningful. This balance between fairness and utility is critical. Users want accurate answers without hidden distortions, but they also expect results tailored to their needs.

Microsoft’s Broader AI Strategy

The move fits neatly into Microsoft’s larger push for responsible AI. The company has already published principles on fairness, accountability, transparency, and safety. Its Responsible AI Standard guides teams on how to design and deploy ethical systems.

This new patent strengthens that framework by embedding fairness directly into technical design. Instead of treating bias as an afterthought, Microsoft is building solutions at the core of its AI infrastructure.

The company has also been proactive in collaborating with policymakers. Earlier this year, it called for global AI regulations that prioritize safety and human rights. By securing patents in this area, Microsoft positions itself as both a technological and ethical leader.

Industry Implications

AI bias is more than a research problem—it is a business issue. Companies that fail to address it risk regulatory penalties, lawsuits, and reputational damage. In Europe, the upcoming AI Act will require transparency and fairness checks for high-risk systems. In the U.S., federal agencies are already reviewing algorithms for potential discrimination.

Microsoft’s patent signals that the company is preparing for this regulatory landscape. It shows investors and customers that the firm takes compliance and trust seriously.

Competitors are likely to follow with their own patents and technical safeguards. The race to build “fair AI” could spark new innovation across the industry. For users, this means better protections and more reliable results.

Looking Ahead

The patent itself is not a finished product. It represents potential technology that may or may not reach commercial rollout. However, it highlights Microsoft’s long-term direction.

As AI tools become deeply embedded in daily life, from search engines to workplace assistants, fairness will remain a key demand. Microsoft’s patent suggests the company wants to meet that demand head-on.

By embedding fairness into its algorithms, Microsoft is not just solving a technical problem. It is building a foundation for the next generation of AI—systems that users can trust to be accurate, relevant, and equitable.

Samsung Patents Modular Support System for Wearable Displays

by

Samsung has secured a new patent that could reshape the future of wearable technology. The company’s latest filing reveals a modular support system for wearable displays. The system promises improved comfort, adaptability, and longevity for devices such as AR and VR headsets.

A New Vision for Wearable Displays

The patent, published in August 2025, outlines a reconfigurable mechanical support framework. Unlike fixed designs, this system lets users swap or reposition modules such as brackets, padding, counterweights, and actuator supports. The goal is simple: make wearables easier to use, easier to repair, and more comfortable to wear.

Samsung’s design includes quick-release mechanisms using snap-locks, magnetic guides, and bayonet-style connectors. These allow users to change modules without tools. The company also highlights alignment features to ensure optical accuracy after adjustments.

How the Modular System Works

The core display remains constant. Around it, modular arms, pads, and support links can be attached or removed. Electromechanical actuators let the headset tilt, pivot, or recline. The design distributes weight more evenly across the head, reducing fatigue during long use.

Modules can also integrate sensors, microphones, or speakers. This means the same headset could support immersive gaming, enterprise training, or industrial safety tasks — all by changing modules.

Comfort Meets Customization

Samsung’s patent stresses the importance of comfort. Traditional AR and VR headsets often cause neck strain and pressure marks. By adding removable padding and counterweights, the modular system balances load more effectively.

For consumers, this translates into lightweight frames for casual media viewing and reinforced mounts for active gaming or industrial applications. For enterprises, it could mean a single device serving multiple roles across a workforce.

Broader Strategy in Wearables

This is not an isolated move. Samsung has filed a series of patents in recent months that focus on wearable adaptability. Earlier filings detailed continuous beamforming microphones, prescription lens integration, and smartglass side-arm speakers. Together, these patents suggest a long-term vision: versatile, modular wearables that adapt to user needs and environments.

Analysts believe Samsung is positioning itself against rivals in the XR (extended reality) space. By focusing on modularity, the company can reduce costs, extend product lifespans, and encourage third-party accessory ecosystems.

Why It Matters

The wearable industry faces three main challenges: comfort, cost, and longevity. A modular support system addresses all three.

  • Comfort: Users get tailored fit and weight distribution.
  • Cost: Replacing modules is cheaper than buying an entire new device.
  • Longevity: Repairability reduces electronic waste and extends product use.

If commercialized, this approach could redefine how consumers and enterprises view wearable hardware. Instead of a single fixed device, headsets may evolve into platforms with swappable modules.

Commercial Outlook

It is important to note that patents are not product announcements. Companies often patent concepts that never reach the market. Still, Samsung’s repeated filings in this field suggest active R&D efforts. Industry experts believe a modular wearable could appear within the next few years, especially as competition intensifies with Apple, Meta, and other XR players.

Challenges Ahead

Despite the promise, challenges remain.

  • Precision alignment: Swappable modules must not affect optical calibration.
  • Connector durability: Fasteners must withstand repeated use.
  • User hygiene: Replaceable padding must be easy to clean.

Overcoming these hurdles will be key for Samsung if it wants to bring this technology to consumers and enterprises.

The Bottom Line

Samsung’s modular support system patent is more than a mechanical innovation. It is a strategic move that signals where the company sees the future of wearables. Customization, adaptability, and sustainability are at its core.

If Samsung delivers on this vision, users could soon own a headset that transforms from lightweight smartglasses to a high-performance VR system with just a few swaps. That future may still be years away, but the blueprint is now on paper.

Assam Doctor Secures Patent for Self-Breast Examination Demonstration Model

by

Dr. Gayatri Gogoi, Associate Professor at Assam Medical College and Hospital (AMCH), has received a design patent for her innovative self-breast examination (SBE) demonstration model. The patent has been granted by the Controller General of Patents, Designs and Trade Marks under Design No. 395195-001.

A Step Towards Early Detection

Breast cancer remains one of the most common cancers among women in India. Despite being an external organ, late detection is frequent due to low awareness and limited screening facilities. Dr. Gogoi designed this model to simplify awareness campaigns and to encourage timely detection of abnormalities.

The Assam Medical College researcher believes that the low-cost model will help women in both urban and rural areas understand the process of self-examination.

Unique Features of the Model

The patented model stands out for its simplicity and accessibility. It is:

  • Safe and eco-friendly
  • Lightweight and portable
  • Made from everyday materials
  • Culturally acceptable for community use

These qualities make it ideal for use by ASHAs (Accredited Social Health Activists) and ANMs (Auxiliary Nurse Midwives).

Training and Implementation

The first phase of the project will focus on training frontline health workers. Once trained, they can demonstrate the model during community health programs. This approach will replace traditional awareness methods that rely only on charts and paper diagrams.

By offering a hands-on demonstration, health workers can help women learn self-breast examination techniques correctly and with confidence.

Potential Impact in Public Health

Dr. Gogoi envisions her innovation as a game changer for primary healthcare. She believes that widespread adoption of the model could significantly improve early detection rates and reduce breast cancer-related deaths in India.

The initiative also highlights the growing role of ICMR Regional Centres in supporting grassroots medical innovations that directly impact communities.

Broader Context

Globally, the effectiveness of structured self-breast examination has been debated. While some health agencies caution against routine self-checks due to false positives, many experts promote breast awareness. The concept encourages women to remain alert to changes in their breasts and to seek medical advice when necessary.

By combining awareness with a simple teaching tool, Dr. Gogoi’s model addresses a major gap in health education.

Silk Nanogel Injector for Targeted Drug Delivery Receives Design Patent in India

by

A team of Indian researchers has secured a design patent for a silk nanogel injector that promises precise and localized drug delivery. The registration was filed on May 15, 2025 and approved on August 28, 2025, according to the Controller General of Patents, Designs and Trademarks.

The new injector uses silk fibroin nanogels, a biocompatible and biodegradable material derived from silk protein. These nanogels can encapsulate therapeutic agents and release them in a sustained and controlled manner. Experts believe this breakthrough will improve cancer therapy, wound healing, and regenerative medicine by reducing side effects and enhancing treatment efficiency.

The Innovation

Unlike conventional injectors, the patented device is designed to deliver drugs directly at the target site. This helps in minimizing systemic exposure. The researchers also highlight that silk nanogels can be tuned for different drug molecules, making the technology versatile for multiple therapies.

The Team Behind the Device

The project brought together scientists from leading institutions across India. Key contributors include:

  • Padmalochan Hembram of Berhampur University
  • Debabrata Mohanty of Xavier University, Bhubaneswar
  • Manasa Kumar Panda of VSS Institute of Medical Research, Burla
  • Laxmi Singh and Maheswari Behera of OUAT, Bhubaneswar
  • Debasis Nayak of MSRCBD University, Baripada
  • Yugal Kishore Mahanta of the University of Meghalaya
  • Suprabhat Mukherjee of Kazi Nazrul University, West Bengal
  • Ghanashyam Behera of Maa Manikeshwari University, Bhawanipatna
  • Mehdi Rahimi, an international collaborator from Iran

Legal Protection

The design registration is valid for 10 years, with an option to extend for another five years. Under India’s Designs Act, 2000, this protection covers the device’s external configuration and design features. While patents safeguard technical functionality, design rights ensure exclusive use of the product’s appearance and structure.

A Step Towards Precision Medicine

The silk nanogel injector adds momentum to India’s growing innovation in drug delivery systems. Researchers are optimistic about its commercial potential in hospitals and clinics, where localized delivery can transform patient care.

Cerence AI Sues Apple Over Patent Infringement Claims

by

Cerence AI has filed a patent infringement lawsuit against Apple, accusing the tech giant of using its innovations without permission. The case was submitted on September 4, 2025, in the U.S. District Court for the Western District of Texas, a frequent venue for intellectual property disputes.


Cerence’s Allegations
Cerence alleges that Apple misused its patented technologies. These patents focus on text input and recognition and voice command monitoring. The company claims Apple embedded these technologies in the iPhone and iPad without securing a license.
The dispute traces back to 2021 when Cerence approached Apple with an acquisition proposal. At that time, it presented detailed patent documentation and claim charts showing potential infringement. However, no agreement was reached.


Official Statement
Jennifer Salinas, Chief Administrative Officer and General Counsel of Cerence, stressed the importance of protecting innovation. She said the lawsuit aims to defend years of research and development. The company is seeking both damages and licensing fees.


Apple’s Response
Apple has yet to issue a detailed statement. Historically, the company has defended itself vigorously in patent cases. Analysts expect this lawsuit may become a drawn-out legal battle.
Industry Impact
Cerence is a leading player in automotive AI, powering voice assistants in over 525 million vehicles worldwide. The lawsuit underlines the growing conflicts between smaller innovators and global tech leaders over patented technologies.
Apple, already familiar with patent disputes, faces renewed scrutiny as courts decide whether its use of Cerence’s inventions violated intellectual property laws.
What’s Next?
The outcome of this case could force Apple to pay licensing fees or modify features in its products. For Cerence, a favorable ruling would strengthen its position as a pioneer in AI-driven communication technologies.

GenBio Files Provisional Patent for Next-Gen Anti-Inflammatory Therapy

by

Biotechnology company GenBio Inc. has announced that it has filed a provisional patent application for Inflamoxil, a next-generation anti-inflammatory therapy. The company said the therapy aims to target chronic inflammation and could also play a role in tackling antibiotic resistance.

GenBio explained that Inflamoxil works by blocking pro-inflammatory cytokines, which are key drivers of inflammation. Researchers believe that the therapy could provide relief to patients suffering from chronic conditions where traditional medicines show limited success.

The company also highlighted that Inflamoxil might boost the effectiveness of antibiotics. By reducing resistance mechanisms, the therapy could extend the usefulness of existing drugs, which are under global threat from rising antimicrobial resistance.

A provisional patent allows inventors to secure an early filing date while continuing to refine their product. GenBio now has 12 months to file a full application to convert this into a nonprovisional patent.

The move reflects the growing urgency in the medical community to address both chronic inflammatory disorders and the public health crisis of antibiotic resistance. Industry experts note that if Inflamoxil progresses successfully through trials, it could serve multiple therapeutic areas.

GenBio stated that its research team is committed to advancing the therapy and will continue laboratory and pre-clinical studies in the coming months.